Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Nokia Corp — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Nokia Corp trades at $10.36 (market cap $56.99B). The key difference: Nokia Corp is far larger — about 9.4× Iovance Biotherapeutics Inc. Common Stock's market cap, and Nokia Corp pays a 1.61% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Nokia Corp for 66 Days on average.
| IOVA | NOK | |
|---|---|---|
Market Cap | $6.04B | $56.99B |
Volume | 14,805,993 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $14.82 | $16.83 |
52-Week Low | $1.81 | $5.18 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $5.97B | $55.01B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nokia (NOK) trades at $10.14, down 4.52% today, amid bearish technical signals but strong analyst support. The stock shows mixed fundamentals with a high P/E ratio of 75.09 but improving revenue trends, with 2026 revenue projected at $20.4B. Recent partnerships with Microsoft and ICEYE for AI and satellite communications highlight growth initiatives. Cash flow volatility remains a concern with negative net cash flow in 2025 and 2026.
The outlook is cautiously optimistic with a consensus price target of $17.50 representing 73% upside potential. Key opportunities include AI infrastructure demand and expanding partnerships, while risks involve cash flow instability and competitive pressures in telecom equipment. Analyst sentiment is strongly bullish with 62% buy ratings, though technical indicators suggest near-term weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
